Dupixent was tested in adolescents and adults with atopic hand-foot dermatitis in what is believed to be the first trial of a biologic therapy in this difficult-to-treat form of the disease.

CSU is a severe form of hives that affects around 1% of ... In CUPID STUDY B, IL-4 and IL-13 inhibitor Dupixent (dupilumab) wasn't able to achieve a significant improvement in symptoms in Xolair ...

If approved, Dupixent would be the first and only targeted ... The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients being more prone ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

The trial also showed that Dupixent significantly reduced disease ... The blisters and rash can form over much of the body and cause the skin to bleed and crust, resulting in patients being ...

Dupixent was previously granted Orphan Drug ... filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024. Any forward-looking ...